Adage Capital Partners’s Kyverna Therapeutics KYTX Stock Holding History

Adage Capital Partners’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.32M	Sell	500,000 -1,166,666	-70%	-$9.72M	0.01%	784
2025 Q4	$15.7M	Buy	+1,666,666	New	+$12.4M	0.02%	562
2024 Q3	–	Sell	-75,000	Closed	-$563K	–	948
2024 Q2	$563K	Sell	75,000 -500,000	-87%	-$7.64M	﹤0.01%	814
2024 Q1	$14.3M	Buy	+575,000	New	+$16M	0.03%	534

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Adage Capital Partners's KYTX Position: Q1 2026 in Review

Adage Capital Partners reduced its Kyverna Therapeutics (KYTX) stake by 70% in Q1 2026, selling an estimated $9.72M and leaving 500,000 shares worth $4.32M. The position accounts for 0.01% of the portfolio, ranked #784.

Adage Capital Partners first reported a position in KYTX in Q1 2024 and has held it in 4 quarters since. The position peaked at $15.7M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Adage Capital Partners held 500,000 shares of Kyverna Therapeutics worth $4.32M as of Q1 2026.
Adage Capital Partners sold 1,166,666 Kyverna Therapeutics shares in Q1 2026, an estimated $9.72M.
Kyverna Therapeutics made up 0.01% of Adage Capital Partners's portfolio in Q1 2026, its #784 holding.
Adage Capital Partners first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 4 quarters since.
Adage Capital Partners's Kyverna Therapeutics position peaked at $15.7M in Q4 2025.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.